Who is the average patient presenting with prostate cancer?
- PMID: 16194711
- DOI: 10.1016/j.urology.2005.06.082
Who is the average patient presenting with prostate cancer?
Abstract
Prostate cancer screening, diagnosis, and treatment have changed dramatically in the last 20 years. Patients with newly diagnosed prostate cancer have many treatment options available. We attempted to determine how patient demographics and quality of life (QOL) have changed, and we describe the average patient with newly diagnosed prostate cancer in the early 21st century. From the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) we identified 3003 men with prostate cancer diagnosed between 1997 and 2003 for whom pretreatment demographic and QOL data were available. All patients completed both the University of California-Los Angeles Prostate Cancer Index (UCLA-PCI) and the Rand Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) as self-administered questionnaires at the time of diagnosis. We compared demographic variables (age at diagnosis, race/ethnicity, education, number of comorbidities, body mass index [BMI], and insurance type), treatment choice, and pretreatment QOL scores on the SF-36 and UCLA-PCI scales for the periods 1997 to 1999 or 2000 to 2003. Stratified analysis by risk category was performed for demographic and QOL data for the 2 periods. Race/ethnicity and insurance demographics were statistically different for the 2 periods. Low-risk patients also showed a statistically increased BMI in the 2000 to 2003 period. Risk category predicted performance on both inventories, with low-risk patients having better function than intermediate-risk patients and high-risk patients in the areas of urinary bother, bowel function and bother, and sexual function and bother, as well as in many general well-being and emotional health scales on the SF-36. We conclude that the "average" prostate cancer patient is white, 65 years of age, overweight, educated at a college level, and has 1 to 2 comorbidities. Patients report average or above-average pretreatment health-related QOL for all scales based on 2 validated instruments. In this cohort, more patients chose radical prostatectomy than any other form of treatment.
Similar articles
-
Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.BJU Int. 2005 Jul;96(1):43-7. doi: 10.1111/j.1464-410X.2005.05564.x. BJU Int. 2005. PMID: 15963118
-
Responsiveness of the University of California-Los Angeles Prostate Cancer Index.Urology. 2010 Jun;75(6):1418-23. doi: 10.1016/j.urology.2009.04.070. Epub 2009 Jul 8. Urology. 2010. PMID: 19589573
-
Quality of life after radical treatment of prostate cancer: validation of the Italian version of the University of California-Los Angeles Prostate Cancer Index.Urology. 2005 Aug;66(2):338-43. doi: 10.1016/j.urology.2005.02.027. Urology. 2005. PMID: 16098363
-
The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.J Urol. 2004 Apr;171(4):1393-401. doi: 10.1097/01.ju.0000107247.81471.06. J Urol. 2004. PMID: 15017184 Review.
-
Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.BJU Int. 2007 Jan;99 Suppl 1:25-9; discussion 30. doi: 10.1111/j.1464-410X.2007.06598.x. BJU Int. 2007. PMID: 17229166 Review.
Cited by
-
The Efficacy and Safety of Tadalafil 5 mg Once Daily in the Treatment of Erectile Dysfunction After Robot-Assisted Laparoscopic Radical Prostatectomy: 1-Year Follow-up.Korean J Urol. 2014 Feb;55(2):112-9. doi: 10.4111/kju.2014.55.2.112. Epub 2014 Feb 14. Korean J Urol. 2014. PMID: 24578807 Free PMC article.
-
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.Eur Urol. 2010 Apr;57(4):622-9. doi: 10.1016/j.eururo.2009.03.077. Epub 2009 Apr 3. Eur Urol. 2010. PMID: 19375843 Free PMC article.
-
Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.World J Urol. 2016 Oct;34(10):1389-95. doi: 10.1007/s00345-016-1789-3. Epub 2016 Feb 22. World J Urol. 2016. PMID: 26902878
-
The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.J Natl Cancer Inst Monogr. 2012 Dec;2012(45):184-90. doi: 10.1093/jncimonographs/lgs041. J Natl Cancer Inst Monogr. 2012. PMID: 23271771 Free PMC article. Clinical Trial.
-
Contrasting roles of the ABCG2 Q141K variant in prostate cancer.Exp Cell Res. 2017 May 1;354(1):40-47. doi: 10.1016/j.yexcr.2017.03.020. Epub 2017 Mar 11. Exp Cell Res. 2017. PMID: 28300564 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous